Purpose: To determine the diagnostic ability of retinal vessel diameter (RVD) measurements and the factors related to retinal vascular diameters in patients with open-angle glaucoma (OAG). Methods: This retrospective observational study included 145 patients with OAG (63 with high-tension and 82 with low-tension glaucoma) and 60 healthy controls. The central retinal arteriolar equivalent (CRAE) and central retinal venular equivalent (CRVE) were measured using the IVAN software version 1.3. Receiver operating characteristic (ROC) curves were obtained for the average retinal nerve fiber layer (RNFL) thickness and RVD indices including CRAE, CRVE, and CRAE/CRVE ratio. Areas under the ROC curves (AUCs), 95% confidence intervals (CIs), and sensitivities at a fixed specificity (>90% and >80%) were calculated. Factors related to CRAE were analyzed by simple and multiple linear regression analyses. Results: Among the RVD indices, the CRAE had the largest AUC for discriminating glaucomatous changes between eyes with glaucoma and those without (0.803; 95% CI, 0.742–0.855). The AUC of CRAE did not significantly differ from that of average RNFL thickness (P = 0.134). However, CRAE showed lower sensitivity than average RNFL thickness at a specificity greater than 90%. Factors significantly associated with CRAE in both simple and multiple linear regression analyses were age, spherical equivalent, average RNFL thickness, presence of diabetes mellitus, and a glaucoma diagnosis (all P ≤ 0.05). Conclusions: The diagnostic ability of CRAE for detecting OAG was good, which was not much worse than that of average RNFL thickness. This finding suggests the potential usefulness of RVD for glaucoma detection.

A single-center retrospective observational case series was conducted. This case series enrolled patients who showed ophthalmic manifestations within one week after COVID-19 vaccination at Korea University Guro Hospital in Seoul, Korea, from May 2021 to January 2022. The medical records of patients who complained of ocular symptoms and showed ophthalmic adverse events within one week after COVID-19 vaccination were reviewed. Seventeen eyes from 16 patients with a mean age of 63.8 (range 33–83) years were included in the case series, and all symptoms developed within 1–7 days following inoculation. Retinal vein occlusion in nine eyes (52.9%), retinal artery occlusion in one eye (5.9%), newly developed anterior uveitis in one eye (5.9%), exacerbation of previously diagnosed panuveitis in two eyes (11.8%), and angle-closure attack with high intraocular pressure in four eyes (23.5%) were included. Twelve patients (75%) had been vaccinated with the AstraZeneca (AZD1222) and four (25%) with the Pfizer (BNT162b2) vaccines. Of these, 10 patients (62.5%) experienced ocular disease exacerbation after the first dose, 4 (25%) after the second dose, and 2 (12.5%) after the third dose (booster shot). Eleven patients (64.7%) underwent tests for hematological abnormalities, and three of them tested positive for anti-PF4 antibodies, but no abnormal findings were noted. A causal relationship between vaccination and the ocular manifestations could not be determined, which is a limitation of this study. However, clinicians should consider the effect of COVID-19 vaccination on ophthalmic disease. Further studies are required to elucidate the possible effects of COVID-19 vaccination on the eye.